cd47 pd l1 Search Results


pd-l1 null mdamb-231 cells  (Synthego Inc)
90
Synthego Inc pd-l1 null mdamb-231 cells
Pd L1 Null Mdamb 231 Cells, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd-l1 null mdamb-231 cells/product/Synthego Inc
Average 90 stars, based on 1 article reviews
pd-l1 null mdamb-231 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-cd47 antibodies  (GenSci Regeneration Sciences)
90
GenSci Regeneration Sciences anti-cd47 antibodies
Anti Cd47 Antibodies, supplied by GenSci Regeneration Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd47 antibodies/product/GenSci Regeneration Sciences
Average 90 stars, based on 1 article reviews
anti-cd47 antibodies - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-cd47/pd-l1 bsab  (HanX Biopharmaceuticals Inc)
90
HanX Biopharmaceuticals Inc anti-cd47/pd-l1 bsab
List of “don’t eat me signaling pathways.
Anti Cd47/Pd L1 Bsab, supplied by HanX Biopharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd47/pd-l1 bsab/product/HanX Biopharmaceuticals Inc
Average 90 stars, based on 1 article reviews
anti-cd47/pd-l1 bsab - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pd-l1 × cd47  (Pharmabcine)
90
Pharmabcine pd-l1 × cd47
Programs in clinical and preclinical stages to enhance tumor immunity for cancer treatment
Pd L1 × Cd47, supplied by Pharmabcine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd-l1 × cd47/product/Pharmabcine
Average 90 stars, based on 1 article reviews
pd-l1 × cd47 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


List of “don’t eat me signaling pathways.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: List of “don’t eat me signaling pathways.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques: Blocking Assay, Activation Assay, Expressing

Depiction of CD47/SIRPα signaling pathway. CD47 is overexpressed on the surface of cancer cells, acting as a “don’t eat me” signal. SIRPα is a receptor on the surface of macrophages and dendritic cells. When CD47 binds to SIRPα, it sends an inhibitory signal to the myeloid cells. This interaction inhibits the phagocytic activity of the myeloid cells, preventing them from engulfing and destroying cancer cells, thus allowing the cancer cells to evade the immune system.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Depiction of CD47/SIRPα signaling pathway. CD47 is overexpressed on the surface of cancer cells, acting as a “don’t eat me” signal. SIRPα is a receptor on the surface of macrophages and dendritic cells. When CD47 binds to SIRPα, it sends an inhibitory signal to the myeloid cells. This interaction inhibits the phagocytic activity of the myeloid cells, preventing them from engulfing and destroying cancer cells, thus allowing the cancer cells to evade the immune system.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques: Activity Assay

Depiction of CD47 and SIRPα structures.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Depiction of CD47 and SIRPα structures.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques:

Depiction of mechanism of actions targeting CD47/SIRPα axis. The anti-SIRPα mAbs bind to SIRPα and SIRPα-Fc fusion proteins bind to FcγR on macrophages (left panel), while anti-CD47 mAbs SIRPα-Fc fusion proteins bind to CD47 on tumor cells (right panel).

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Depiction of mechanism of actions targeting CD47/SIRPα axis. The anti-SIRPα mAbs bind to SIRPα and SIRPα-Fc fusion proteins bind to FcγR on macrophages (left panel), while anti-CD47 mAbs SIRPα-Fc fusion proteins bind to CD47 on tumor cells (right panel).

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques:

Categories for CD47 antagonist products.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Categories for CD47 antagonist products.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques:

CD47 antagonists currently entering clinical trials for treatment of ovarian cancers.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: CD47 antagonists currently entering clinical trials for treatment of ovarian cancers.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques:

CD47 related ongoing clinical trials in breast cancers.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: CD47 related ongoing clinical trials in breast cancers.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques:

CD47 antagonists currently entering clinical trials for treatment of lymphomas.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: CD47 antagonists currently entering clinical trials for treatment of lymphomas.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques:

CD47 agents currently entering clinical trials for treatment of hematological malignancies except lymphoma.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: CD47 agents currently entering clinical trials for treatment of hematological malignancies except lymphoma.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques: Transplantation Assay

Targeting CD47 related clinical trials have been terminated.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Targeting CD47 related clinical trials have been terminated.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques: Binding Assay, Mutagenesis

Prerequisites for macropage activation. In a normal situation, CD47 binds to SIRPα, acting as the “don’t eat me” signal, and no “eat me” signal is present. Therefore, there is no or poor macrophage activation (A) . When only CD47 is blocked, the “don’t eat me” signal is inhibited. However, no “eat me” signal is activated, resulting in only limited macrophage activation (B) . When the CD47 “don’t eat me” signal is present, and only the Fc-receptor “eat me” signal is activated, there is still only limited macrophage activation (C) . When both CD47 is blocked and the Fc-receptor “eat me” signal is activated, full macrophage activation occurs (D) .

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Prerequisites for macropage activation. In a normal situation, CD47 binds to SIRPα, acting as the “don’t eat me” signal, and no “eat me” signal is present. Therefore, there is no or poor macrophage activation (A) . When only CD47 is blocked, the “don’t eat me” signal is inhibited. However, no “eat me” signal is activated, resulting in only limited macrophage activation (B) . When the CD47 “don’t eat me” signal is present, and only the Fc-receptor “eat me” signal is activated, there is still only limited macrophage activation (C) . When both CD47 is blocked and the Fc-receptor “eat me” signal is activated, full macrophage activation occurs (D) .

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques: Activation Assay

Potential tactics for future exploration of CD47-targeted therapeutic agents.

Journal: Frontiers in Oncology

Article Title: Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

doi: 10.3389/fonc.2024.1378647

Figure Lengend Snippet: Potential tactics for future exploration of CD47-targeted therapeutic agents.

Article Snippet: NCT05189093 , HX-009 (HX-009–5) , Phase II , Recruiting , 99 , HanX Biopharmaceuticals Inc , CD47 antagonist , anti-CD47/PD-L1 BsAb , Lymphoma.

Techniques: Modification, Plasmid Preparation, Blocking Assay, Activation Assay

Programs in clinical and preclinical stages to enhance tumor immunity for cancer treatment

Journal: Antibody Therapeutics

Article Title: Biology drives the discovery of bispecific antibodies as innovative therapeutics

doi: 10.1093/abt/tbaa003

Figure Lengend Snippet: Programs in clinical and preclinical stages to enhance tumor immunity for cancer treatment

Article Snippet: PMC-122 , PharmAbcine , PD-L1 × CD47 , Preclinical , Target cell depletion , Enhance phagocytosis , Not disclosed , NA.

Techniques:

Programs in clinical and preclinical stages to promote target cell depletion for cancer treatment

Journal: Antibody Therapeutics

Article Title: Biology drives the discovery of bispecific antibodies as innovative therapeutics

doi: 10.1093/abt/tbaa003

Figure Lengend Snippet: Programs in clinical and preclinical stages to promote target cell depletion for cancer treatment

Article Snippet: PMC-122 , PharmAbcine , PD-L1 × CD47 , Preclinical , Target cell depletion , Enhance phagocytosis , Not disclosed , NA.

Techniques: